Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 9/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 3/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13388282 | 0.84 | MAPK1 (0.41) | MAPK1HPGDPOLBCDK2CCNA2 | |
| SCHEMBL1907701 | 0.80 | SMN1; SMN2 (0.36) | MAPTSMN1; SMN2HTT | |
| SCHEMBL13388276 | 0.79 | MAPK1 (0.38) | MAPK1HPGDPOLBCDK2CCNA2 | |
| SCHEMBL13387504 | 0.79 | GPR84 (0.37) | POLB | |
| SCHEMBL13387526 | 0.78 | MAPT (0.35) | HPGDPOLBMAPTCDK2CCNA2 | |
| SCHEMBL1907702 | 0.76 | MME (0.33) | SMN1; SMN2CDK2CCNA2CCNA1 | |
| Trifluoroacetic Acid SCHEMBL1907045 | 0.75 | SSTR3 (0.34) | — | |
| Trifluoroacetic Acid SCHEMBL13387652 | 0.72 | CPB2 (0.40) | MAPK1 | |
| SCHEMBL13387759 | 0.71 | NQO2 (0.37) | MAPT | |
| SCHEMBL1906671 | 0.71 | HDAC3 (0.38) | MAPK1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481494-B2 | Compounds for the treatment of diseases related to protein misfolding | UNIVERSITAT DUISBURG-ESSEN (DE) | 2013-07-09 | — | — | US | disclosed |
| US-20120270795-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES RELATED TO PROTEIN MISFOLDING | UNIVERSITAT DUISBURG-ESSEN (DE) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270795-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES RELATED TO PROTEIN MISFOLDING | APP, PRNP, PSEN1 | MAPK1 1482/4885HPGD 1496/4885POLB 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.